The invention relates to a diagnostic assay for selectively measuring
levels of the 35kD form of thrombin-activatable fibrinolysis inhibitor
(TAFIa or TAFIai), or a derivative or variant thereof, but not the TAFI
proenzyme (TAFI) or the N-terminal activation peptide of TAFI.